Cargando…
A favorable inductive remission rate for decitabine combined with chemotherapy as a first course in <60‐year‐old acute myeloid leukemia patients with myelodysplasia syndrome features
In acute myeloid leukemia (AML), myelodysplasia‐related changes contribute to a poor prognosis. This retrospective, propensity score‐matched study analyzed 108 newly diagnosed AML patients with features of myelodysplasia syndrome (MDS) (aged 14‐60 years) from 2014 to 2018, who received either idarub...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718585/ https://www.ncbi.nlm.nih.gov/pubmed/31322840 http://dx.doi.org/10.1002/cam4.2418 |
_version_ | 1783447750343393280 |
---|---|
author | Liu, Fengqi Wang, Hehua Liu, Junru Zhou, Zhenhai Zheng, Dong Huang, Beihui Su, Chang Zou, Waiyi Xu, Duorong Tong, Xiuzhen Li, Juan |
author_facet | Liu, Fengqi Wang, Hehua Liu, Junru Zhou, Zhenhai Zheng, Dong Huang, Beihui Su, Chang Zou, Waiyi Xu, Duorong Tong, Xiuzhen Li, Juan |
author_sort | Liu, Fengqi |
collection | PubMed |
description | In acute myeloid leukemia (AML), myelodysplasia‐related changes contribute to a poor prognosis. This retrospective, propensity score‐matched study analyzed 108 newly diagnosed AML patients with features of myelodysplasia syndrome (MDS) (aged 14‐60 years) from 2014 to 2018, who received either idarubicin and cytarabine (IA) or decitabine, idarubicin and cytarabine (DAC+IA), and compared efficacy and toxicity between the two regimens. After propensity score matching, there were 54 patients in each group. The rate of complete remission (CR) was higher in the DAC+IA group than in the IA group (85.2% vs 68.5%, P = .040) after the first course, and toxicities were comparable in both groups. Multivariate analysis indicated that the combination with DAC was independent factor for CR rate after the first induction therapy (OR = 2.978, 95% CI:1.090‐8.137, P = .033). Subgroup analysis showed a CR advantage for DAC+IA (vs IA) for patients of intermediate‐high risk status according to National Comprehensive Cancer Network prognostic stratification. In conclusion, DAC+IA is therefore offered as a new induction choice for newly diagnosed AML patients with features of MDS, aged <60 years old, especially in intermediate‐high risk status. |
format | Online Article Text |
id | pubmed-6718585 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-67185852019-09-06 A favorable inductive remission rate for decitabine combined with chemotherapy as a first course in <60‐year‐old acute myeloid leukemia patients with myelodysplasia syndrome features Liu, Fengqi Wang, Hehua Liu, Junru Zhou, Zhenhai Zheng, Dong Huang, Beihui Su, Chang Zou, Waiyi Xu, Duorong Tong, Xiuzhen Li, Juan Cancer Med Clinical Cancer Research In acute myeloid leukemia (AML), myelodysplasia‐related changes contribute to a poor prognosis. This retrospective, propensity score‐matched study analyzed 108 newly diagnosed AML patients with features of myelodysplasia syndrome (MDS) (aged 14‐60 years) from 2014 to 2018, who received either idarubicin and cytarabine (IA) or decitabine, idarubicin and cytarabine (DAC+IA), and compared efficacy and toxicity between the two regimens. After propensity score matching, there were 54 patients in each group. The rate of complete remission (CR) was higher in the DAC+IA group than in the IA group (85.2% vs 68.5%, P = .040) after the first course, and toxicities were comparable in both groups. Multivariate analysis indicated that the combination with DAC was independent factor for CR rate after the first induction therapy (OR = 2.978, 95% CI:1.090‐8.137, P = .033). Subgroup analysis showed a CR advantage for DAC+IA (vs IA) for patients of intermediate‐high risk status according to National Comprehensive Cancer Network prognostic stratification. In conclusion, DAC+IA is therefore offered as a new induction choice for newly diagnosed AML patients with features of MDS, aged <60 years old, especially in intermediate‐high risk status. John Wiley and Sons Inc. 2019-07-19 /pmc/articles/PMC6718585/ /pubmed/31322840 http://dx.doi.org/10.1002/cam4.2418 Text en © 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Cancer Research Liu, Fengqi Wang, Hehua Liu, Junru Zhou, Zhenhai Zheng, Dong Huang, Beihui Su, Chang Zou, Waiyi Xu, Duorong Tong, Xiuzhen Li, Juan A favorable inductive remission rate for decitabine combined with chemotherapy as a first course in <60‐year‐old acute myeloid leukemia patients with myelodysplasia syndrome features |
title | A favorable inductive remission rate for decitabine combined with chemotherapy as a first course in <60‐year‐old acute myeloid leukemia patients with myelodysplasia syndrome features |
title_full | A favorable inductive remission rate for decitabine combined with chemotherapy as a first course in <60‐year‐old acute myeloid leukemia patients with myelodysplasia syndrome features |
title_fullStr | A favorable inductive remission rate for decitabine combined with chemotherapy as a first course in <60‐year‐old acute myeloid leukemia patients with myelodysplasia syndrome features |
title_full_unstemmed | A favorable inductive remission rate for decitabine combined with chemotherapy as a first course in <60‐year‐old acute myeloid leukemia patients with myelodysplasia syndrome features |
title_short | A favorable inductive remission rate for decitabine combined with chemotherapy as a first course in <60‐year‐old acute myeloid leukemia patients with myelodysplasia syndrome features |
title_sort | favorable inductive remission rate for decitabine combined with chemotherapy as a first course in <60‐year‐old acute myeloid leukemia patients with myelodysplasia syndrome features |
topic | Clinical Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718585/ https://www.ncbi.nlm.nih.gov/pubmed/31322840 http://dx.doi.org/10.1002/cam4.2418 |
work_keys_str_mv | AT liufengqi afavorableinductiveremissionratefordecitabinecombinedwithchemotherapyasafirstcoursein60yearoldacutemyeloidleukemiapatientswithmyelodysplasiasyndromefeatures AT wanghehua afavorableinductiveremissionratefordecitabinecombinedwithchemotherapyasafirstcoursein60yearoldacutemyeloidleukemiapatientswithmyelodysplasiasyndromefeatures AT liujunru afavorableinductiveremissionratefordecitabinecombinedwithchemotherapyasafirstcoursein60yearoldacutemyeloidleukemiapatientswithmyelodysplasiasyndromefeatures AT zhouzhenhai afavorableinductiveremissionratefordecitabinecombinedwithchemotherapyasafirstcoursein60yearoldacutemyeloidleukemiapatientswithmyelodysplasiasyndromefeatures AT zhengdong afavorableinductiveremissionratefordecitabinecombinedwithchemotherapyasafirstcoursein60yearoldacutemyeloidleukemiapatientswithmyelodysplasiasyndromefeatures AT huangbeihui afavorableinductiveremissionratefordecitabinecombinedwithchemotherapyasafirstcoursein60yearoldacutemyeloidleukemiapatientswithmyelodysplasiasyndromefeatures AT suchang afavorableinductiveremissionratefordecitabinecombinedwithchemotherapyasafirstcoursein60yearoldacutemyeloidleukemiapatientswithmyelodysplasiasyndromefeatures AT zouwaiyi afavorableinductiveremissionratefordecitabinecombinedwithchemotherapyasafirstcoursein60yearoldacutemyeloidleukemiapatientswithmyelodysplasiasyndromefeatures AT xuduorong afavorableinductiveremissionratefordecitabinecombinedwithchemotherapyasafirstcoursein60yearoldacutemyeloidleukemiapatientswithmyelodysplasiasyndromefeatures AT tongxiuzhen afavorableinductiveremissionratefordecitabinecombinedwithchemotherapyasafirstcoursein60yearoldacutemyeloidleukemiapatientswithmyelodysplasiasyndromefeatures AT lijuan afavorableinductiveremissionratefordecitabinecombinedwithchemotherapyasafirstcoursein60yearoldacutemyeloidleukemiapatientswithmyelodysplasiasyndromefeatures AT liufengqi favorableinductiveremissionratefordecitabinecombinedwithchemotherapyasafirstcoursein60yearoldacutemyeloidleukemiapatientswithmyelodysplasiasyndromefeatures AT wanghehua favorableinductiveremissionratefordecitabinecombinedwithchemotherapyasafirstcoursein60yearoldacutemyeloidleukemiapatientswithmyelodysplasiasyndromefeatures AT liujunru favorableinductiveremissionratefordecitabinecombinedwithchemotherapyasafirstcoursein60yearoldacutemyeloidleukemiapatientswithmyelodysplasiasyndromefeatures AT zhouzhenhai favorableinductiveremissionratefordecitabinecombinedwithchemotherapyasafirstcoursein60yearoldacutemyeloidleukemiapatientswithmyelodysplasiasyndromefeatures AT zhengdong favorableinductiveremissionratefordecitabinecombinedwithchemotherapyasafirstcoursein60yearoldacutemyeloidleukemiapatientswithmyelodysplasiasyndromefeatures AT huangbeihui favorableinductiveremissionratefordecitabinecombinedwithchemotherapyasafirstcoursein60yearoldacutemyeloidleukemiapatientswithmyelodysplasiasyndromefeatures AT suchang favorableinductiveremissionratefordecitabinecombinedwithchemotherapyasafirstcoursein60yearoldacutemyeloidleukemiapatientswithmyelodysplasiasyndromefeatures AT zouwaiyi favorableinductiveremissionratefordecitabinecombinedwithchemotherapyasafirstcoursein60yearoldacutemyeloidleukemiapatientswithmyelodysplasiasyndromefeatures AT xuduorong favorableinductiveremissionratefordecitabinecombinedwithchemotherapyasafirstcoursein60yearoldacutemyeloidleukemiapatientswithmyelodysplasiasyndromefeatures AT tongxiuzhen favorableinductiveremissionratefordecitabinecombinedwithchemotherapyasafirstcoursein60yearoldacutemyeloidleukemiapatientswithmyelodysplasiasyndromefeatures AT lijuan favorableinductiveremissionratefordecitabinecombinedwithchemotherapyasafirstcoursein60yearoldacutemyeloidleukemiapatientswithmyelodysplasiasyndromefeatures |